Probiotics and Helicobacter pylori-associated diseases: From targeted prevention to improving the effectiveness of eradication therapy
Abstract. Helicobacter pylori (H. pylori), which occurs in more than 40% of the world’s population, is recognized as a key factor in the development of gastritis, peptic ulcer disease and stomach cancer. All infected individuals are recommended for eradication, but its effectiveness, in the face of growing antibiotic resistance, falls short of the target threshold of 90% in many regions of the world. Due to the important role of microbiota in the development and progression of gastric pathology, the possibility of using probiotics has attracted the attention of the medical community among strategies to improve the effectiveness of anti-Helicobacter therapy. Lactobacillus reuteri DSM 17648 inactivated strain is of particular interest in this regard. Given the biological properties and characteristics of this strain, as well as clinical trials data, the use of products containing it may be considered as part of anti-Helicobacter therapy to increase its effectiveness and reduce the risk of adverse events. Furthermore, the use of Lactobacillus reuteri DSM 17648 is possible in cases of contraindications to eradication therapy to reduce the bacterial load and as a preventative measure against H. pylori infection.M.A. Livzan, O.V. Gaus
Keywords
Helicobacter pylori
chronic gastritis
gastric microbiota
probiotics
eradication therapy
Lactobacillus reuteri DSM 17648
References
1. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT et al.; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V / Florence Consensus Report. Gut. 2017;66(1):6–30.
PMID: 27707777. https://doi.org/10.1136/gutjnl-2016-312288
2. Rugge M, Genta RM, Malfertheiner P, Dinis-Ribeiro M, El-Serag H, Graham DY et al.; RE.GA.IN; RE GA IN. RE.GA.IN.: The real-world gastritis initiative-updating the updates. Gut. 2024;73(3):407–41.
PMID: 38383142. https://doi.org/10.1136/gutjnl-2023-331164
3. Chen YC, Malfertheiner P, Yu HT, Kuo CL, Chang YY, Meng FT et al. Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022. Gastroenterology. 2024;166(4):605–19.
PMID: 38176660. https://doi.org/10.1053/j.gastro.2023.12.022
4. Бордин Д.С., Янова О.Б., Абдулхаков Р.А., Цуканов В.В., Ливзан М.А., Бурков С.Г. с соавт. Европейский регистр Helicobacter pylori (протокол Hp-EuReg): первые результаты Российских центров. Терапевтический архив. 2016;88(2):33–38. (Bordin DS, Yanov OB, Abdulkhakov RA, Tsukanov VV, Livzan MA, Burkov SG et al. European Helicobacter pylori Register (Hp-EuReg Protocol): First results from Russian Centers. Terapevticheskiy arkhiv = Therapeutic Archive. 2016;88(2):33–38 (In Russ.)).
EDN: VOONON. https://doi.org/10.17116/terarkh201688233-38
5. Andreev DN, Khurmatullina AR, Maev IV, Bordin DS, Abdulkhakov SR, Kucheryavyy YA et al. The prevalence of Helicobacter pylori infection in the adult population of Russia: A systematic review and meta-analysis. Epidemiologia (Basel). 2025;6(3):47.
PMID: 40843706. PMCID: PMC12372033. https://doi.org/10.3390/epidemiologia6030047
6. Ливзан М.А., Гаус О.В., Мозговой С.И. Хронический атрофический гастрит: тактика курации пациента. РМЖ. Медицинское обозрение. 2021;5(6):427–432. (Livzan MA, Gaus OV, Mozgovoi SI. Chronic atrophic gastritis: Patient management. Russkiy meditsinskiy zhurnal. Meditsinskoye obozreniye = Russian Medical Inquiry. 2021;5(6):427–432 (In Russ.)).
EDN: UAXHUG. https://doi.org/10.32364/2587-6821-2021-5-6-427-432
7. Бордин Д.С., Мозговой С.И., Ливзан М.А., Гаус О.В., Маев И.В. Междисциплинарный консенсус RE.GA.IN.: что нового? Часть 1: понятие о норме, Helicobacter pylori-ассоциированный и аутоиммунный гастрит. Эффективная фармакотерапия. 2024;20(2):54–70. (Bordin DS, Mozgovoy SI, Livzan MA, Gaus OV, Maev IV. Interdisciplinary consensus RE.GA.IN.: What’s new? Part 1: Concept of normality, Helicobacter pylori-associated and autoimmune gastritis. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2024;20(2):54–70 (In Russ.)).
EDN: QYFEYT. https://doi.org/10.33978/2307-3586-2024-20-2-54-70
8. Peek RM. Helicobacter pylori infection and disease: From humans to animal models. Dis Model Mech. 2008;1(1):50–55.
PMID: 19048053 https://doi.org/10.1242/dmm.000364
9. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–89.
PMID: 11556297. https://doi.org/10.1056/NEJMoa001999
10. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.
PMID: 38572751. https://doi.org/10.3322/caac.21834
11. Lai Y, Wei W, Du Y, Gao J, Li Z. Biomaterials for Helicobacter pylori therapy: Therapeutic potential and future perspectives. Gut Microbes. 2022;14(1):2120747.
PMID: 36070564. https://doi.org/10.1080/19490976.2022.2120747
12. Salvatori S, Marafini I, Laudisi F, Monteleone G, Stolfi C. Helicobacter pylori and gastric cancer: Pathogenetic mechanisms. Int J Mol Sci. 2023;24(3):2895.
PMID: 36769214. https://doi.org/10.3390/ijms24032895
13. Livzan MA, Mozgovoi SI, Gaus OV, Shimanskaya AG, Kononov AV. Histopathological evaluation of gastric mucosal atrophy for predicting gastric cancer risk: Problems and solutions. Diagnostics (Basel). 2023;13(15):2478.
PMID: 37568841. https://doi.org/10.3390/diagnostics13152478
14. Ливзан М.А., Мозговой С.И., Кононов А.В. Гастрит после эрадикации Helicobacter pylori – простые следы или серьезные последствия? Лечащий врач. 2011;(7):7. (Livzan MA, Mozgovoy SI, Kononov AV. Gastritis after Helicobacter pylori eradication – simple traces or serious consequences? Lechashchiy vrach = Attending Physician. 2011;(7):7 (In Russ.)). EDN: SGXSLD.
15. Zhang L, Zhao M, Fu X. Gastric microbiota dysbiosis and Helicobacter pylori infection. Front Microbiol. 2023;14:1153269.
PMID: 37065152. https://doi.org/10.3389/fmicb.2023.1153269
16. Chen CC, Liou JM, Lee YC, Hong TC, El-Omar EM, Wu MS. The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 2021;13(1):1–22.
PMID: 33938378. https://doi.org/10.1080/19490976.2021.1909459
17. Aumpan N, Mahachai V, Vilaichone RK. Management of Helicobacter pylori infection. JGH Open. 2022;7(1):3–15.
PMID: 36660052. https://doi.org/10.1002/jgh3.12843
18. Pereira-Marques J, Ferreira RM, Machado JC, Figueiredo C. The influence of the gastric microbiota in gastric cancer development. Best Pract Res Clin Gastroenterol. 2021;50–51:101734.
PMID: 33975676. https://doi.org/10.1016/j.bpg.2021.101734
19. Schulz C, Schutte K, Koch N, Vilchez-Vargas R, Wos-Oxley ML, Oxley APA et al. The active bacterial assemblages of the upper GI tract in individuals with and without Helicobacter infection. Gut. 2018;67(2):216–25.
PMID: 27920199. https://doi.org/10.1136/gutjnl-2016-312904
20. Guo Y, Zhang Y, Gerhard M, Gao JJ, Mejias-Luque R, Zhang L et al. Effect of Helicobacter pylori on gastrointestinal microbiota: A population-based study in Linqu, a high-risk area of gastric cancer. Gut. 2020;69(9):1598–607.
PMID: 31857433. PMCID: PMC7456744. https://doi.org/10.1136/gutjnl-2019-319696
21. Клинические рекомендации. Гастрит и дуоденит. Российская гастроэнтерологическая ассоциация, Ассоциация «Эндоскопическое общество “РЭндО”», Межрегиональная общественная организация «Научное сообщество по содействию клиническому изучению микробиома человека», Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 708_2. Доступ: https://cr.minzdrav.gov.ru/preview-cr/708_2 (дата обращения – 20.01.2026). (Clinical guidelines. Gastritis and duodenitis. Russian Gastroenterological Association, Endoscopic Society “REnDO”, Scientific Community for Promoting Clinical Study of the Human Microbiome, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 708_2. URL: https://cr.minzdrav.gov.ru/preview-cr/708_2 (date of access – 20.01.2026) (In Russ.)).
22. Клинические рекомендации. Язвенная болезнь. Российская гастроэнтерологическая ассоциация, Общероссийская общественная организация «Российское общество хирургов», Российское общество колоректальных хирургов, Ассоциация «Эндоскопическое общество “РЭндО”», Межрегиональная общественная организация «Научное сообщество по содействию клиническому изучению микробиома человека». Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 277_2. Доступ: https://cr.minzdrav.gov.ru/preview-cr/277_2 (дата обращения – 20.01.2026). (Clinical guidelines. Peptic ulcer disease. Russian Gastroenterological Association, Russian Society of Surgeons, Russian Society of Colorectal Surgeons, Endoscopic Society “REnDO”, Scientific Community for the Promotion of Clinical Study of the Human Microbiome. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 277_2. URL: https://cr.minzdrav.gov.ru/preview-cr/277_2 (date of access – 20.01.2026) (In Russ.)).
23. Han YM, Park JM, Jeong M, Yoo JH, Kim WH, Shin SP et al. Dietary, non-microbial intervention to prevent Helicobacter pylori-associated gastric diseases. Ann Transl Med. 2015;3(9):122.
PMID: 26207250. PMCID: PMC4481371. https://doi.org/10.3978/j.issn.2305-5839.2015.03.50
24. Yuan L, Yang C, Han Y, Yang F, Tu H. Beyond antibiotics: Probiotics as a promising ally against Helicobacter pylori. Front Pharmacol. 2025;16:1620870.
PMID: 40717984. https://doi.org/10.3389/fphar.2025.1620870
25. Homan M, Orel R. Are probiotics useful in Helicobacter pylori eradication? World J Gastroenterol. 2015;21(37):10644–53.
PMID: 26457024. https://doi.org/10.3748/wjg.v21.i37.10644
26. Qureshi N, Li P, Gu Q. Probiotic therapy in Helicobacter pylori infection: A potential strategy against a serious pathogen? Appl Microbiol Biotechnol. 2019;103(4):1573–88.
PMID: 30610283. https://doi.org/10.1007/s00253-018-09580-3
27. Ji J, Yang H. Using probiotics as supplementation for Helicobacter pylori antibiotic therapy. Int J Mol Sci. 2020;21(3):1136.
PMID: 32046317. https://doi.org/ 10.3390/ijms21031136
28. Zagari RM, Frazzoni L, Marasco G, Fuccio L, Bazzoli F. Treatment of Helicobacter pylori infection: A clinical practice update. Minerva Med. 2021;112(2):281–87.
PMID: 32700868. https://doi.org/ 10.23736/S0026-4806.20.06810-X
29. Tanashat M, Abuelazm M, Abouzid M, Al-Ajlouni YA, Ramadan A, Alsalah S et al. Efficacy of probiotics regimens for Helicobacter pylori eradication: A systematic review, pairwise, and network meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2025;65:424–44.
PMID: 39642994. https://doi.org/ 10.1016/j.clnesp.2024.11.016
30. Casas Deza D, Alcedo J, Lafuente M, Lopez FJ, Perez-Aisa A, Pavoni M et al.; Hp-EuReg investigators. Probiotics prescribed with Helicobacter pylori eradication therapy in Europe: Usage pattern, effectiveness, and safety. Results from the European Registry on Helicobacter pylori Management (Hp-EuReg). Am J Gastroenterol. 2025;120(11):2644–59.
PMID: 39902822. https://doi.org/10.14309/ajg.0000000000003351
31. Holz C, Busjahn A, Mehling H, Arya S, Boettner M, Habibi H, Lang C. Significant reduction in Helicobacter pylori load in humans with non-viable Lactobacillus reuteri DSM17648: A pilot study. Probiotics Antimicrob Proteins. 2015;7(2):91–100.
PMID: 25481036. PMCID: PMC4415890. https://doi.org/10.1007/s12602-014-9181-3
32. Jiang J, Li K, Xiao Y, Zhong A, Tang J, Duan Y, Li Z. Limosilactobacillus reuteri regulating intestinal function: A review. Fermentation. 2023;9(1):19.
https://doi.org/10.3390/fermentation9010019
33. Ismail NI, Nawawi KNM, Hsin DCC, Hao KW, Mahmood NRKN, Chearn GLC et al. Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial. Helicobacter. 2023;28(6):e13017.
PMID: 37614081. https://doi.org/10.1111/hel.13017
34. Ivashkin V, Maev I, Poluektova E, Sinitsa A, Avalueva E, Mnatsakanyan M et al. Efficacy and safety of postbiotic contained inactivated Lactobacillus reuteri ( Limosilactobacillus reuteri ) DSM 17648 as adjuvant therapy in the eradication of Helicobacter pylori in adults with functional dyspepsia: A randomized double-blind placebo-controlled trial. Clin Transl Gastroenterol. 2024;15(9):e1.
PMID: 39023173. PMCID: PMC11421730. https://doi.org/10.14309/ctg.0000000000000750
35. Бордин Д.С., Войнован И.Н., Хомерики С.Г., Янова О.Б., Ким В.А., Быстровская Е.В., Шишин К.В. Эффективность и безопасность Lactobacillus reuteri DSMZ17648 у инфицированных Helicobacter pylori. Лечащий врач. 2016;(5):106. (Bordin DS, Voynovan IN, Khomeriki SG, Yanova OB, Kim VA, Bystrovskaya EV, Shishin KV. Efficacy and safety of Lactobacillus reuteri DSMZ17648 in patients infected with Helicobacter pylori. Lechashchiy vrach = Attending Physician. 2016;(5):106 (In Russ.)). EDN: WANIUV.
About the Authors
Maria A. Livzan, MD, Dr. Sci (Medicine), professor, corresponding member of the Russian Academy of Sciences, rector and head of the Department of faculty therapy and gastroenterology, Omsk State Medical University, Omsk, Russian Federation.E-mail: mlivzan@yandex.ru
ORCID: https://orcid.org/0000-0002-6581-7017. Scopus ID: 24341682600. eLibrary SPIN: 1961-4082
Olga V. Gaus, MD, PhD (Medicine), associate professor, professor of the Department of faculty therapy and gastroenterology, Omsk State Medical University, Omsk, Russian Federation.
E-mail: gaus_olga@bk.ru
ORCID: https://orcid.org/0000-0001-9370-4768. Scopus ID: 56598554900. eLibrary SPIN: 7116-8419
Similar Articles
